0001209191-18-021991.txt : 20180328 0001209191-18-021991.hdr.sgml : 20180328 20180328201008 ACCESSION NUMBER: 0001209191-18-021991 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180327 FILED AS OF DATE: 20180328 DATE AS OF CHANGE: 20180328 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clark Mitchall G. CENTRAL INDEX KEY: 0001612094 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 18720262 MAIL ADDRESS: STREET 1: C/O ATARA BIOTHERAPEUTICS, INC. STREET 2: 3260 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-278-8930 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-27 0 0001604464 Atara Biotherapeutics, Inc. ATRA 0001612094 Clark Mitchall G. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP & Chief R & QA Officer Common Stock 2018-03-27 4 M 0 28848 25.15 A 212368 D Common Stock 2018-03-27 4 M 0 32500 22.72 A 244868 D Common Stock 2018-03-27 4 M 0 11406 11.00 A 256274 D Common Stock 2018-03-27 4 S 0 22794 36.43 D 233480 D Common Stock 2018-03-27 4 S 0 31356 37.10 D 202124 D Common Stock 2018-03-27 4 S 0 29980 38.23 D 172144 D Common Stock 2018-03-27 4 S 0 2170 39.53 D 169974 D Common Stock 2018-03-27 4 S 0 2800 40.40 D 167174 D Common Stock 2018-03-27 4 S 0 11103 41.10 D 156071 D Employee Stock Option (Right to Buy) 25.15 2018-03-27 4 M 0 28848 0.00 D 2022-01-16 Common Stock 28848 11194 D Employee Stock Option (Right to Buy) 22.72 2018-03-27 4 M 0 32500 0.00 D 2022-12-17 Common Stock 32500 32500 D Employee Stock Option (Right to Buy) 11.00 2018-03-27 4 M 0 11406 0.00 D 2021-10-14 Common Stock 11406 3125 D Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.70 to $36.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.75 to $37.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.80 to $38.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.85 to $39.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.00 to $40.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. 1/48th of the shares subject to the stock option vest and become exercisable each month following January 16, 2015. 1/48th of the shares subject to the stock option vest and become exercisable each month following December 17, 2015. 1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014. /s/ David Tucker, Attorney-in-Fact for Mitchall G. Clark 2018-03-28